Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20576592 | 0.88 | MEN1 (0.56) | RAB9ASMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL29489965 | 0.87 | RAB9A (0.45) | RAB9ASMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL22805168 | 0.87 | RAB9A (0.45) | RAB9ASMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL21833959 | 0.86 | EGFR (0.46) | RAB9ASMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL22827746 | 0.84 | RAB9A (0.52) | RAB9ASMN1; SMN2MAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29489971 | 0.83 | RAB9A (0.51) | RAB9ASMN1; SMN2MAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL20577413 | 0.83 | RAB9A (0.51) | RAB9ASMN1; SMN2MAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29365947 | 0.83 | RAB9A (0.51) | RAB9ASMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL29072267 | 0.81 | RAB9A (0.52) | RAB9ASMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL28698173 | 0.80 | MEN1 (0.44) | RAB9ASMN1; SMN2MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986565-B1 | NEW EGFR INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-11117890-B2 | Substituted isoindole allosteric EGFR inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3749664-A1 | COMPOUNDS WHICH CAUSE DEGRADATION OF EGFR, FOR USE AGAINST CANCER | F. Hoffmann-La Roche AG (CH) | 2020-12-16 | — | — | EP | disclosed |
| US-20200361930-A1 | BIFUNCTIONAL MOLECULES THAT DEGRADE EGFR | HOFFMANN-LA ROCHE INC. (US) | 2020-11-19 | — | — | US | disclosed |
| EP-3630754-A1 | COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102299-A1 | COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-04-02 | — | — | US | disclosed |
| WO-2019149922-A1 | COMPOUNDS WHICH CAUSE DEGRADATION OF EGFR, FOR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2019-08-08 | — | — | WO | disclosed |
| WO-2018220149-A1 | COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361930-A1 | BIFUNCTIONAL MOLECULES THAT DEGRADE EGFR | EGFR, ERBB2, MDM2 | RAB9A 1495/4885SMN1; SMN2 4694/4885MAPK1 2619/4885 |
| US-11117890-B2 | Substituted isoindole allosteric EGFR inhibitors | EGFR, ERBB2, ERBB3 | RAB9A 1272/4885SMN1; SMN2 4646/4885MAPK1 513/4885 |
| US-20200102299-A1 | COMPOUNDS | EGFR, ERBB2, ERBB3 | RAB9A 1251/4885SMN1; SMN2 4344/4885MAPK1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.